Barclays
ELDN icon

Barclays’s Eledon Pharmaceuticals ELDN Stock Holding History

Barclays’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$92.2K Buy
36,445
+24,556
+207% +$82.5K ﹤0.01% 4340
2026
Q2 		$46.8K Sell
11,889
-1,927
-14% -$7.01K ﹤0.01% 4339
2026
Q1 		$42.6K Sell
13,816
-73,656
-84% -$173K ﹤0.01% 4379
2025
Q4 		$132K Buy
87,472
+7,719
+10% +$18.3K ﹤0.01% 4493
2025
Q3 		$207K Sell
79,753
-22,125
-22% -$64.7K ﹤0.01% 4272
2025
Q2 		$276K Buy
101,878
+31,878
+46% +$95.6K ﹤0.01% 4086
2025
Q1 		$237K Hold
70,000
– – ﹤0.01% 3947
2024
Q4 		$288K Buy
+70,000
New +$276K ﹤0.01% 4137
2019
Q2 		– Sell
-4
Closed – – 7007
2019
Q1 		$0 Buy
+4
New +$265 ﹤0.01% 7077
2018
Q4 		– Hold
0
– – – 7032
2018
Q3 		– Hold
0
– – – 7192
2018
Q2 		– Sell
-1
Closed -$103 – 7034
2018
Q1 		$0 Buy
+1
New +$74 ﹤0.01% 7123
2017
Q4 		– Hold
0
– – – 6962
2017
Q3 		– Sell
-3
Closed -$249 – 6890
2017
Q2 		$0 Sell
3
-73
-96% -$7.44K ﹤0.01% 6708
2017
Q1 		$10K Buy
76
+51
+204% +$7.49K ﹤0.01% 6069
2016
Q4 		$4K Buy
25
+19
+317% +$3.64K ﹤0.01% 6182
2016
Q3 		$1K Buy
6
+4
+200% +$1.46K ﹤0.01% 6381
2016
Q2 		$2K Buy
2
+1
+100% +$1.1K ﹤0.01% 5943
2016
Q1 		$1K Sell
1
-2
-67% -$1.96K ﹤0.01% 5956
2015
Q4 		$4K Buy
+3
New +$5.23K ﹤0.01% 5612
2015
Q3 		– Sell
-1
Closed -$2.06K – 6878
2015
Q2 		$2K Hold
1
– – ﹤0.01% 6790
2015
Q1 		$2K Sell
1
-2
-67% -$4.41K ﹤0.01% 6860
2014
Q4 		$7K Buy
+3
New +$7.12K ﹤0.01% 6875

Other funds holding ELDN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Triumph Capital Management
Triumph Capital Management Denver, Colorado $573M AUM 15.32% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Daytona Street Capital
Daytona Street Capital Saint Louis, Missouri $141M AUM 14.38% 1-Year Est. Return

Barclays's ELDN Position: Q3 2026 in Review

Barclays increased its Eledon Pharmaceuticals (ELDN) stake by 207% in Q3 2026, buying an estimated $82.5K and bringing the position to 36,445 shares worth $92.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4340.

Barclays first reported a position in ELDN in Q4 2014 and has held it in 20 quarters since. The position peaked at $288K in Q4 2024. 78 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

  • Barclays held 36,445 shares of Eledon Pharmaceuticals worth $92.2K as of Q3 2026.
  • Barclays bought 24,556 Eledon Pharmaceuticals shares in Q3 2026, an estimated $82.5K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4340 holding.
  • Barclays first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
  • Barclays's Eledon Pharmaceuticals position peaked at $288K in Q4 2024.
  • 78 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.